SCCM Resource Library-Clinical Evidence Necessary to Support Clinical Guidelines for the Use of HDTs

Clinical Evidence Necessary to Support Clinical Guidelines for the Use of HDTs

Video Transcription

Video Summary

The speaker, a member of the NIH COVID Guidelines panel, discusses the complexities of using FDA-authorized and NIH-recommended treatments in the context of COVID-19. They explain the FDA's role in ensuring safety and efficacy of drugs, noting that it doesn't advise on which is best for specific conditions. The discussion includes how clinicians use already-approved drugs off-label based on available medical evidence. Guidelines recommend treatments based on best evidence, which evolves during pandemics. They emphasize the importance of rigorous evaluation in forming guidelines, which often differ from FDA emergency use authorizations.

Asset Caption

90-Minute Session | Clinical Evidence for Host-Directed Therapeutics

Meta Tag

Content Type Presentation

Membership Level Professional

Membership Level Select

Year 2024

Keywords

COVID-19 treatments

FDA authorization

NIH guidelines

off-label drug use

pandemic evidence

	Society of Critical Care Medicine 500 Midway Drive Mount Prospect, IL 60056 USA Phone: +1 847 827-6888 Fax: +1 847 439-7226 Email: support@sccm.org	Contact Us About SCCM Newsroom Advertising & Sponsorship DONATE	MySCCM LearnICU Patients & Families Surviving Sepsis Campaign Critical Care Societies Collaborative	GET OUR NEWSLETTER
© Society of Critical Care Medicine. All rights reserved. \| Privacy Statement \| Terms & Conditions The Society of Critical Care Medicine, SCCM, and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.